Transcatheter aortic valve replacement (TAVR) with a self-expanding intra-annular transcatheter heart valve in patients with severe aortic stenosis (AS) at high-risk for surgery has clinical outcomes comparable with the currently available valves, a 5-year analysis of the PORTICO IDE trial shows.